Cabozantinib in high grade neuroendocrine neoplasms – Interim results from a Phase II trial

#3762

Introduction: Patients with high grade neuroendocrine neoplasms (HG-NENs) have limited treatment options. Cabozantinib, a multi kinase inhibitor can affect tumor growth and metastasis.

Aim(s): To assess the safety and efficacy of cabozantinib monotherapy as a salvage treatment in patients with HG-NENs.

Materials and methods: Patients with HG-NENs (excluding SCLC) that have progressed on first line therapy are treated with cabozantinib 60 mg po daily on Days 1-21 of each 21-day cycle. Treatment continues until unacceptable SAEs, tumor progression, patient decision or death. The primary objective is response rate (RR), secondary objectives being safety, overall survival (OS) and progression-free survival (PFS). The study was designed in two stages: Fourteen patients to be accrued in the first stage and if >1 partial response (PR), an additional 18 patients to be added.

Conference:

Presenting Author: Trikalinos N

Authors: Trikalinos N, Pedersen K, Tan B, Amin M, Rama S,

Keywords: Cabozantinib, high-grade, neuroendocrine, neoplasm, clinical trial,